Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus

Watcharoot Kanchongkittiphon; Nora Kabil; Leonard B. Bacharier; Maleewan Kitcharoensakkul

doi:10.1016/j.jaip.2019.08.052

Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus

Watcharoot Kanchongkittiphon, Nora Kabil, Leonard B. Bacharier, Maleewan Kitcharoensakkul

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1115-1116
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.jaip.2019.08.052
State	Published - Mar 2020

Access to Document

10.1016/j.jaip.2019.08.052

Cite this

@article{17b886e1017f4672b1e39372e4f4135f,

title = "Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus",

author = "Watcharoot Kanchongkittiphon and Nora Kabil and Bacharier, {Leonard B.} and Maleewan Kitcharoensakkul",

note = "Funding Information: Conflicts of interest: L. B. Bacharier has worked as a consultant for DBV, Merck, Boehringer Ingelheim, Vectura, Sanofi, Teva, Novartis/Genentech, GlaxoSmithKline, Circassia, and Regeneron; received honoraria for being on the Speakers Bureau for Teva, Boehringer Ingelheim, Novartis, AstraZeneca, and Sanofi/Regeneron; received research support from Sanofi and Vectura; has research interests: National Institutes of Health/National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases; and has organizational interests in the following: the American Academy of Allergy, Asthma & Immunology Annual Meeting Planning Committee, Journal of Allergy and Clinical Immunology Associate Editor, and Director of American Board of Allergy and Immunology, GINA Science Committee. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = mar,

doi = "10.1016/j.jaip.2019.08.052",

language = "English",

volume = "8",

pages = "1115--1116",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

number = "3",

}

TY - JOUR

T1 - Ecallantide

T2 - An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus

AU - Kanchongkittiphon, Watcharoot

AU - Kabil, Nora

AU - Bacharier, Leonard B.

AU - Kitcharoensakkul, Maleewan

N1 - Funding Information: Conflicts of interest: L. B. Bacharier has worked as a consultant for DBV, Merck, Boehringer Ingelheim, Vectura, Sanofi, Teva, Novartis/Genentech, GlaxoSmithKline, Circassia, and Regeneron; received honoraria for being on the Speakers Bureau for Teva, Boehringer Ingelheim, Novartis, AstraZeneca, and Sanofi/Regeneron; received research support from Sanofi and Vectura; has research interests: National Institutes of Health/National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases; and has organizational interests in the following: the American Academy of Allergy, Asthma & Immunology Annual Meeting Planning Committee, Journal of Allergy and Clinical Immunology Associate Editor, and Director of American Board of Allergy and Immunology, GINA Science Committee. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85072634168&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2019.08.052

DO - 10.1016/j.jaip.2019.08.052

M3 - Article

C2 - 31541765

AN - SCOPUS:85072634168

SN - 2213-2198

VL - 8

SP - 1115

EP - 1116

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 3

ER -

Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus

Access to Document

Other files and links

Cite this